{"created":"2023-06-19T07:25:18.769646+00:00","id":13005,"links":{},"metadata":{"_buckets":{"deposit":"bf6953fa-0ecd-4464-8604-7dc58c9e0f89"},"_deposit":{"created_by":4,"id":"13005","owners":[4],"pid":{"revision_id":0,"type":"depid","value":"13005"},"status":"published"},"_oai":{"id":"oai:gifu-pu.repo.nii.ac.jp:00013005","sets":["147:223"]},"author_link":["18177","18176","18178"],"item_1_biblio_info_14":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2015-06-30","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"55","bibliographicPageStart":"46","bibliographicVolumeNumber":"64","bibliographic_titles":[{"bibliographic_title":"岐阜薬科大学紀要"},{"bibliographic_title":"The annual proceedings of Gifu Pharmaceutical University","bibliographic_titleLang":"en"}]}]},"item_1_creator_6":{"attribute_name":"著者名(日)","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"多田, 幸雄"}],"nameIdentifiers":[{"nameIdentifier":"18176","nameIdentifierScheme":"WEKO"}]}]},"item_1_creator_7":{"attribute_name":"著者名よみ","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"タダ, ユキオ"}],"nameIdentifiers":[{"nameIdentifier":"18177","nameIdentifierScheme":"WEKO"}]}]},"item_1_creator_8":{"attribute_name":"著者名(英)","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"TADA, Yukio","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"18178","nameIdentifierScheme":"WEKO"}]}]},"item_1_description_1":{"attribute_name":"ページ属性","attribute_value_mlt":[{"subitem_description":"P(論文)","subitem_description_type":"Other"}]},"item_1_description_11":{"attribute_name":"抄録(日)","attribute_value_mlt":[{"subitem_description":"I 型アレルギー反応は、肥満細胞に結合しているIgE に抗原が結合することで、細胞内顆粒に貯蔵されている各種\nケミカルメディエーターが放出されることにより惹起される。既存の抗アレルギー薬は、メディエーター遊離抑制薬およ\nび、ヒスタミンH1 拮抗薬、トロンボキサン阻害薬、ロイコトリエン拮抗薬であった。そこで、I 型アレルギー反応の原\n因である IgE の作用を特異的に阻害できればアレルギー疾患の根本的な治療に繋がると考え、従来のメカニズムとは異\nなる新しい抗アレルギー薬の開発を目指した。メチル基転移反応がアレルギー反応に関わっているのではないかという考\nえに基づき、生体内メチル基供与体であるS-adenosylmethionine はsulfonium 化合物であることと、S-methylmethionine\n(methylmethionine sulfonium chloride) がモルモットの抗体産生を増強することから、これをシード化合物とした。次いで、\nsulfonium 化合物の種々の物理化学的性質と抗アレルギー作用および急性毒性との構造活性相関解析による、論理的な分\n子設計を実施した。その結果、抗アレルギー薬: Suplatast Tosilate として認可されたsulfonium 化合物54b を創製するこ\nとができた。","subitem_description_type":"Other"}]},"item_1_description_12":{"attribute_name":"抄録(英)","attribute_value_mlt":[{"subitem_description":"Type I allergic reactions are caused by various chemical mediators released from mast cell by combining antigens and IgE\nantibodies. The existing anti-allergic drugs are mediator suppressants, histamine H1 antagonists, thromboxane inhibitors, and\nleukotriene antagonists. However, drugs that specifically inhibit IgE activity are expected to be efficacious for the treatment of type I\nallergic diseases. We sought to develop a new anti-allergy drug that functions outside the conventional mechanism.\nMethylmethionine sulfonium chloride (S-methylmethionine) was selected as a seed compound, because it reinforces guinea pig\nantibody production and may affect allergic reactions. We analyzed the structure-activity relationship between physical chemical\nproperties and sulfonium compound-induced anti-allergic action or toxicity for rational molecular drug design. Based on these efforts,\nwe identified sulfonium compound 54b, which was launched as Suplatast Tosilate.","subitem_description_type":"Other"}]},"item_1_source_id_13":{"attribute_name":"雑誌書誌ID","attribute_value_mlt":[{"subitem_source_identifier":"AA1258935X","subitem_source_identifier_type":"NCID"}]},"item_1_text_10":{"attribute_name":"著者所属(英)","attribute_value_mlt":[{"subitem_text_language":"en","subitem_text_value":"Interdisciplinary Graduate School of Science and Engineering, Tokyo Institute of Technology"}]},"item_1_text_2":{"attribute_name":"記事種別(日)","attribute_value_mlt":[{"subitem_text_value":"総説"}]},"item_1_text_3":{"attribute_name":"記事種別(英)","attribute_value_mlt":[{"subitem_text_language":"en","subitem_text_value":"Review"}]},"item_1_text_9":{"attribute_name":"著者所属(日)","attribute_value_mlt":[{"subitem_text_value":"東京工業大学大学院総合理工研究科"}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2015-12-08"}],"displaytype":"detail","filename":"スルホニウム化合物の物理化学的性質に基づいた抗アレルギー薬の開発.pdf","filesize":[{"value":"336.2 kB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"スルホニウム化合物の物理化学的性質に基づいた抗アレルギー薬の開発","url":"https://gifu-pu.repo.nii.ac.jp/record/13005/files/スルホニウム化合物の物理化学的性質に基づいた抗アレルギー薬の開発.pdf"},"version_id":"d1ee3724-6bbe-43ca-a3d7-d8441b324628"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"IgE","subitem_subject_scheme":"Other"},{"subitem_subject":"抗アレルギー薬","subitem_subject_scheme":"Other"},{"subitem_subject":"sulfonium 化合物","subitem_subject_scheme":"Other"},{"subitem_subject":"Suplatast Tosilate","subitem_subject_scheme":"Other"},{"subitem_subject":"IgE","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"anti-allergic drug","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"sulfonium compound","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Suplatast Tosilate","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"スルホニウム化合物の物理化学的性質に基づいた抗アレルギー薬の開発","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"スルホニウム化合物の物理化学的性質に基づいた抗アレルギー薬の開発"},{"subitem_title":"Development of Anti-allergic Drugs Using the Physicochemical Properties of a Sulfonium Compound","subitem_title_language":"en"}]},"item_type_id":"1","owner":"4","path":["223"],"pubdate":{"attribute_name":"公開日","attribute_value":"2015-12-08"},"publish_date":"2015-12-08","publish_status":"0","recid":"13005","relation_version_is_last":true,"title":["スルホニウム化合物の物理化学的性質に基づいた抗アレルギー薬の開発"],"weko_creator_id":"4","weko_shared_id":-1},"updated":"2023-06-19T09:00:46.371886+00:00"}